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Cancer is an increasingly important public health 
problem in developing countries, including Africa [1]. As 
public and professional awareness of the cancer problem 
has grown, so has interest in the pattern of disease 
presentation, its epidemiology and treatment outcome. 
To date, however, there has been limited research about 
breast cancer in Africa. In the absence of systematic 
population-based cancer registration, most information 
has come from small clinical and pathology case series 
and the bias inherent in these types of studies has 
inﬂ   uenced current understanding of the pattern and 
characteristics of breast cancer in Africa.
In this communication, we review the evidence for an 
emerging epidemic of breast cancer in Africa, its risk 
factors and likely future course. We conclude that, 
despite limited data, rising incidence of breast cancer is 
being driven by increasing life expectancy, improved 
control of infectious diseases, and changing lifestyle, diet, 
physical activity and obstetric practices. We also review 
current beliefs about hormone receptor subtypes of 
breast cancer in Africa and suggest that this is probably 
not systematically diﬀ   erent from the pattern in other 
populations after adjusting for factors such as age and 
that the reported diﬀ  erences are related to poor tissue 
handling and laboratory processing practices.
Global trends in cancer epidemiology
From an estimated 12 million new cases and 7.6 million 
deaths in 2008, the incidence of cancer worldwide is 
expected to rise to 26.4 million with 17 million deaths by 
2030. Most of these new cases of cancer are expected to 
occur in the developing world, particularly India and 
China [2]. Current data suggest that cancer kills more 
people than HIV/AIDS, tuberculosis and malaria com-
bined, but this overall picture hides signiﬁ  cant variations 
in incidence in diﬀ   erent parts of the world. Whereas 
cancer incidence is certainly rising in all developing 
countries, the poor control and persistence of old 
infectious diseases and emergence of new ones in Africa 
means that infections remain the major source of 
morbidity and mortality in this part of the world 
compared to Asia and Latin America, where the impact 
of non-communicable diseases has now become more 
predominant.
Demographic change and breast cancer in Africa
In general, breast and other cancers are not rare in Africa. 
Th  e probability that a woman who lives to age 65 in 
Kampala would develop a cancer is only 20% lower than 
that of her European contemporary [3]. What diﬀ  ers 
markedly is the probability that the African woman will 
live to be 65 years of age compared to women in 
developed countries. Even if incidence is held constant, 
the change in this probability as a result of increased life 
expectancy at birth is an important cause of the 
increasing prevalence of breast cancer in Africa [4]. A 
comparison of the rate of change of the breast cancer at-
risk population of a typical African country, Nigeria, with 
that of a developed country, France (a clue to the choice 
of these two countries lies in their performance at the 
2010 Football World Cup in South Africa) shows that 
whereas the size of the at-risk population remains largely 
stable in France, it is increasing steeply in Nigeria 
(Figure 1). In France the breast cancer at-risk population 
increased from approximately 19 million women in 1990 
to approximately 21 million in 2010 and is projected to 
remain at approximately 21 million over the next 
10 years. In Nigeria on the other hand, the number of 
women at risk of breast cancer increased steadily from 
approximately 24.5 million in 1990 to approximately 
40  million in 2010 and is projected to rise to over 
50 million by 2020.
Epidemiological risk factors of breast cancer
Incidence is not likely to be constant, however, and the 
direction of its change is related to changes in the 
epidemiological risk factors for breast cancer [5]. Th  e 
incidence of breast cancer starts to increase at about the  © 2010 BioMed Central Ltd
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50 years, when the rate of increase reduces somewhat, 
and by 75 years of age the incidence starts to decline. Th  is 
pattern has been observed in all populations with 
adequate data for analysis. Th   e established risk factors for 
breast cancer include age, sex, age at onset of menarche, 
age at ﬁ  rst full-term pregnancy, parity, breast feeding, age 
at onset of menopause, obesity and physical activity [5]. 
Th   e direction of change in these risk factors in Africa is 
towards increasing incidence of breast cancer [4,5]. Age 
at onset of menarche is reducing because of improved 
nutrition and reduced physical activity. Increased 
demands for education and modern lifestyle choices are 
delaying the age at ﬁ   rst full-term pregnancy and the 
fertility rate of African women, which is also contributing 
to reduced total lifetime breast feeding duration.
Analysis of African breast cancer cases and controls 
studied in Ibadan showed an association with height 
(adjusted odds ratio 1.05, 95% conﬁ  dence interval 1.01 to 
1.08), a marker for nutrition in early life and with waist-
hip ratio (adjusted odds ratio 2.67, 95% conﬁ  dence inter-
val 1.05 to 6.80) [6,7].
A birth cohort analysis of the control participants 
recruited from 1998 to 2007 as part of a case-control 
study of the genetic risk factors of breast cancer in 
African women clearly demonstrates the eﬀ  ect of birth 
cohort on the epidemiological risk factors of breast 
cancer in African women. Comparing women born in the 
decades before 1940 with those born after 1960, the age 
at onset of menarche fell from 16.4 years to 15.3 years. 
Similarly, parity declined from 6 to 4 while the cumulative 
duration of breast feeding fell from an average of 
120 months to 60 months [8]. Th   ese parameters still have 
some way to go before approximating western ﬁ  gures, 
suggesting that further changes will contribute to further 
increases in breast cancer incidence.
Early onset breast cancer in African women
Most African countries at this time have cone-shaped 
population pyramids, a reﬂ   ection of high fertility rate 
coupled with high infant mortality rate; therefore, the 
majority of citizens are children and young adults with 
very little elderly populations. Th   e median age is 
generally 20 years and below. In contrast, the population 
pyramids of developed countries approaches a cylinder in 
shape with more balanced distribution across all age 
groups and median age of about 40 years or higher 
(Figure  2). Because the African population has a low 
median age, breast cancer among young women com  prises 
a higher proportion of the cases presenting in African 
clinics than among older women [3-5]. Th  is  demography-
driven phenomenon has often been misinterpreted to 
suggest that breast cancer in African women tends to 
preferentially aﬀ  ect the young and that this reﬂ  ects some 
intrinsic biological signiﬁ  cance, but this is not so [3]. Th  e 
misunderstanding derives from inappropriate compari-
son of the mean age at clinical presentation obtainable 
from clinical and pathology case series with age incidence 
data from populations with functional cancer registries 
and interpreted to suggest signiﬁ  cant diﬀ  erences in age 
incidence of breast cancer comparing African women 
with women in developed countries.
Breast cancer among young women in any population 
tends to be clinically and pathologically aggressive, with 
rapid progression and a higher mortality rate compared 
to older women [9]. Because the African population is 
predominantly young and African breast cancer patients 
tend to be young, the pattern of breast cancer that 
presents to practitioners in Africa is mostly aggressive in 
clinical course with a high fatality rate. Th  is is not an 
intrinsic African pattern of breast cancer, rather another 
manifestation of the demographic structure of the 
population.
Molecular subtypes of breast cancer in Africa
Another area of controversy in breast cancer in Africa is 
the characterization of the hormone receptor subtypes in 
the patient population. Several studies have suggested 
that African breast cancers are predominantly hormone 
receptor poor [10]. Pathologists and researchers working 
in low resource countries have encountered problems 
related to poor preparation and ﬁ  xation of tissue samples, 
which has often led to inability to apply advanced 
immunohistochemical and molecular biology techniques 
[11]. Th  ese problems include poorly quality specimens 
from large and necrotic tumors, prolonged delay before 
ﬁ   xation, questionable quality of ﬁ  xative  materials, 
prolonged stay in ﬁ  xative (often for several weeks), poor 
Figure 1. Comparison of the change in the relative proportion of 
breast cancer at-risk population in Nigeria and France from 1990 
to 2020.
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control practices [11].
More systematic studies of breast cancer in Africa have 
not conﬁ  rmed the suggestion that African breast tumors 
are predominantly receptor poor [11,12]. Given that 
similar claims have been made of breast cancer subtypes 
in other parts of the world and these have also been 
found to be untrue after careful studies and the wide 
variation in genetic and environmental characteristics of 
the diﬀ   erent low resource environments where these 
observations had been made, poor tissue preparation 
rather than intrinsic biological characteristics is the likely 
reason for the results seen in some studies [11,13]. 
Compounding the problem of immunohistochemistry of 
breast tumors is the lack of methodological standard-
ization even in developed countries, resulting in up to 
20% variation in false positives and negatives and 
suboptimal utilization of the information currently 
generated by receptor assays [14].
Signifi  cance of these controversies
Despite improved understanding of the epidemiology of 
breast cancer and the impact of the current African 
demographic pattern on the age distribution, breast 
cancer aﬀ   ects many young and middle-aged African 
women at the most active phase of their social and 
economic life, resulting in signiﬁ  cant economic, social, 
physical and psychological harm [9]. Research and imple-
mentation of methods of eﬀ   ective early detection, 
eﬀ  ective but low-cost, low-tech treatment of early onset 
breast cancer, and management of the social, economic 
and psychological sequelae of the disease are urgently 
required [15,16]. African breast cancer patients must be 
oﬀ  ered hormonal therapy where the hormone receptor 
status is unknown because of lack of immuno  histo-
chemical services. Th  ese are relatively inexpensive with 
tolerable toxicity proﬁ  les. Development of managed ‘hub 
and spoke’ regional pathology laboratory model systems 
that support several hospitals will improve the quality of 
pathology services and reduce cost. Training of clinicians 
and laboratory technicians to ensure proper tissue 
sampling and ﬁ   xation is critical and of the foremost 
importance [11]. Much work remains to be done in order 
to better understand breast cancer in African women.
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